{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"data_sharing_plan":["IPD Sharing (as of October 2019): No"],"condition":["Colorectal cancer metastatic","Colorectal Cancer","Colorectal Neoplasms","K-Ras wild type metastatic colorectal cancer"],"disease":["K-ras Wild Type Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2098880"],"location":["Austria","Belgium","Hungary","France","Spain"],"study_start_month":["12"],"keyword":["Standard cetuximab + FOLFIRI","First line metastatic","K-Ras wildtype","Erbitux 5 mg/ml solution for infusion","Cetuximab","Dose escalation cetuximab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer","description":"The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study the molecular signatures of response.","dates":{"creation":"2010-12-15"},"accession":"2098880","cross_references":{"ClinicalTrials___gov":["NCT01251536"],"EU Clinical Trials Register":["2009-009992-36"]}}